Yinghui Shi

Mar 5, 2024 | bmccancer.biomedcentral.com | Jingjing Duan |Yinghui Shi |weixue Wang |Tongtong Wang |Tao Ning |Le Fu Zhang | +8 more

Between January 2013 and December 2020, 183 patients with mCRC who met the inclusion and exclusion criteria from the Tianjin Medical University Cancer Institute and Hospital were selected. Among them, 143 patients received chemotherapy ± targeted drugs, and the remaining 40 patients were given anti-angiogenic monotherapy. The baseline disease characteristics at the index date of third-line therapy were listed in Table 1.